Ann: Appendix 4E and Annual Report, page-24

First 24 Last

Share
Profile

Follow
JPGuru

4,660 Posts.

568

23/08/21

09:55

Post #: 55489366
Share

Originally posted by tinyteddy: ↑

The company is not allowed to advertise that it''s available on Special Access Scheme. On social media or anywhere else.

Vrs I agree, but the fact is they did get a CE Mark and they can sell it in EU. I think you need to remember that there are very very few options for these patients. This isn't a new antihypertensive or cholesterol agent. This is likely the factor that swayed the CE assessors, and the same will apply to FDA. FDA has shown this year with Alzheimers, than where there are few options, they will take a balanced look at studies and outcomes. The TGA won;t - Australia has a derivative scientific community and the rigidity is a sign of immaturity not wisdom. NZ is different too - it's frankly typical and ridiculous that NZ has approved it and Australia hasn't.

So, I agree the evidence isn't perfect, but in the face of limited options, some doctors will offer it.

The original sirtex trial was tiny (although controlled) and the larger definitive studies subsequently showed no OS benefit. Yet they developed a solid business because there are limited options and anecdotally the docs felt it had benefit. Then the studies flow after approval and add to the evidence. Same with oncosil. Doctors will use it a bit, then publish their own experience outside of pivotal studies.

Expand

Well said "The TGA won;t - Australia has a derivative scientific community and the rigidity is a sign of immaturity not wisdom."

Last edited by JPGuru: 23/08/21

OSL Price at posting: 5.0¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

First 24 Last

Add OSL (ASX) to my watchlist

(20min delay)
Last 1.4¢		Change 0.000(0.00%)		Mkt cap ! $52.97M

Open	High	Low	Value	Volume
1.4¢	1.4¢	1.3¢	$13.00K	963.1K

Buyers (Bids)

No.	Vol.	Price($)
17	9962616	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.4¢	5510744	7

View Market Depth

No.	Vol.	Price($)
17	9962616	0.013
18	9668351	0.012
18	8704466	0.011
17	11298020	0.010
11	4231223	0.009

Price($)	Vol.	No.
0.014	5510744	7
0.015	2993570	11
0.016	4392825	5
0.017	5155548	3
0.018	1632208	4

Last trade - 16.10pm 07/10/2024 (20 minute delay)

OSL (ASX) Chart

Ann: Appendix 4E and Annual Report, page-24

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Appendix 4E and Annual Report, page-24

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News